Patents Assigned to Genentech
  • Oxadiazolones as transient receptor potential channel inhibitors
    Patent number: 10913742
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
  • PYRIDINE LACTAM COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210032271
    Abstract: The invention provides compounds having the general formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R7a, R7b, X, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of use thereof.
    Type: Application
    Filed: October 9, 2020
    Publication date: February 4, 2021
    Applicant: Genentech, Inc.
    Inventor: Snahel Patel
  • ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
    Publication number: 20210032345
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: April 21, 2020
    Publication date: February 4, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Polynucleotides encoding optimized variants of anti-VEGF antibodies
    Patent number: 10906968
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 2, 2021
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • Protein purification methods
    Patent number: 10906934
    Abstract: The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: February 2, 2021
    Assignee: GENENTECH, INC.
    Inventors: Arick Brown, Junyan Ji, Jun Liu, Yuchang John Wang
  • Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
    Patent number: 10906918
    Abstract: The present disclosure provides for methods for preparing tricyclic PI3K inhibitor compounds in high yield and purity in aqueous solvent systems.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 2, 2021
    Assignee: Genentech, Inc.
    Inventors: Andreas Stumpf, Remy Angelaud, Andrew McClory, Herbert Yajima, Chudi Ndubaku, Alan Olivero
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 10906986
    Abstract: Provided herein are methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: February 2, 2021
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • METHODS FOR DETECTING AND QUANTIFYING FGF21
    Publication number: 20210025890
    Abstract: The presently disclosed subject matter provides antibodies that bind FGF21 and methods of using the same. In particular, the present disclosure provides immunoassay methods for detecting and quantifying active and total FGF21 levels in a sample and kits for performing such methods.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 28, 2021
    Applicant: GENENTECH, INC.
    Inventors: John Hok Nin Lowe, Junichiro Sonoda
  • METHOD FOR TREATING JOINT DAMAGE
    Publication number: 20210024643
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Application
    Filed: May 5, 2020
    Publication date: January 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • IRAK4 modulators
    Patent number: 10899774
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, Naomi S. Rajapaksa, James Richard Kiefer, Jr.
  • Optimized variants of anti-vegf antibodies and methods of use thereof in treatment
    Patent number: 10899828
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • IRAK4 modulators
    Patent number: 10899772
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Tamiko Katsumoto, Jun Liang, Naomi S. Rajapaksa, James Richard Kiefer, Jr., Liqiang Fu
  • Substituted benzamides useful as sodium channel blockers
    Patent number: 10899732
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 26, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-an Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Ivan William Hemeon, Steven McKerrall, Brian Salvatore Safina, Tao Sheng, Dan Sutherlin
  • Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
    Patent number: 10898570
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Anti-Polyubiquitin Antibodies
    Publication number: 20210017260
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: June 29, 2020
    Publication date: January 21, 2021
    Applicant: Genentech Inc.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS
    Publication number: 20210015920
    Abstract: The present disclosure provides liquid formulations comprising polypeptides and surfactants. In particular, it discloses a liquid formulation comprising a polypeptide and a surfactant, wherein at least about 70% (wt %) of the surfactant are isosorbide polyoxyethylene (POE) fatty acid esters. The invention also provides methods for making such liquid formulations, articles of manufacture comprising such liquid formulations and methods of treating a patient with such liquid formulations.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Anthony TOMLINSON, Barthelemy Luc DEMEULE, Isidro Angelo Eleazar ZARRAGA
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20210015919
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Graham A. Ross
  • CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION
    Publication number: 20210017488
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
  • Method of culturing eukaryotic cells
    Patent number: 10894940
    Abstract: An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 19, 2021
    Assignee: GENENTECH, INC.
    Inventors: Dinesh Baskar, Jenny Hsiung, Woon-Lam Susan Leung, Inn H. Yuk
  • ANTI-OX40 ANTIBODIES AND METHODS OF USE
    Publication number: 20210009705
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Application
    Filed: June 24, 2020
    Publication date: January 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, Kevin WALSH, Patricia DE ALMEIDA, James ANDYA, Ye SHEN